For instance, high expression of ATB and MALAT1 lncRNAs correlates with poor survival in PCa patients, highlighting a potential role as early indicators of prognosis.[11,12] Meanwhile, low expression of PCAT29, which can act as an androgen-regulated tumor suppressor lncRNA, was shown to be correlated with poor prognosis in PCa,[13] whereas high lncRNA SCHLAP1 levels were also associated with poor clinical outcome in patients with clinically localized PCa after radical prostatectomy.[14]. Here, SCHLAP1 is linked to posterior cortical atrophy.